News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 17:04:37 10/12/2024 GMT			5-day change	1st Jan Change
91.92 ^USD	+1.46%		-0.82%	+13.23%

04:09pm	Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating	MT
03:43pm	Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Keeps Outperform Rating	MT

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating	03:09pm	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Keeps Outperform Rating	02:43pm	MT
Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy	12-09	MT
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024	12-09	BU
Kite, Gilead Company, Announces Results from Five-Year Follow-Up Analysis of ZUMA-5, Phase 2 Study of Yescarta in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas Including Follicular Lymphoma or Marginal Zone Lymphoma	12-09	CI
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits	12-09	BU
Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and Exposition	12-09	CI
Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH	12-08	CI
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH	12-08	BU
Gilead Sciences Seeks Small Acquisitions	12-04	CI
Gilead Sciences, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 11:40 AM	12-04
HSBC Adjusts Price Target on Gilead Sciences to $82 From $69	12-04	MT
Gilead Sciences Insider Sold Shares Worth $23,065,271, According to a Recent SEC Filing	12-03	MT
Gilead Sciences, Inc. Presents at Piper Sandler 36th Annual Healthcare Conference, Dec-03-2024 11:00 AM	12-03
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors	12-03	MT
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target	12-03	BU
Gilead Sciences, Inc. and Tubulis Enter into Exclusive Option and License Agreement to Discover and Develop Antibody-Drug Conjugate Against Solid Tumor Target	12-03	CI
European Commission Secures 2.3 Million Doses of Gilead's COVID-19 Drug	12-02	MT
Jefferies Raises Price Target on Gilead Sciences to $115 From $105	12-02	MT
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results	11-27	BU
Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results	11-27	CI
Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic	11-26	AQ
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.	11-25	AQ
UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating	11-22	MT
Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90	11-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Filters